Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Drops By 62.8%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 150,700 shares, a decrease of 62.8% from the December 15th total of 405,200 shares. Currently, 10.2% of the shares of the company are sold short. Based on an average trading volume of 325,900 shares, the days-to-cover ratio is presently 0.5 days.

Coeptis Therapeutics Stock Performance

Shares of NASDAQ COEP traded up $0.12 during midday trading on Tuesday, hitting $8.12. The company’s stock had a trading volume of 43,243 shares, compared to its average volume of 447,495. The stock has a fifty day moving average price of $4.33 and a 200 day moving average price of $4.33. The company has a current ratio of 0.40, a quick ratio of 0.40 and a debt-to-equity ratio of 0.03. Coeptis Therapeutics has a one year low of $2.31 and a one year high of $13.58. The firm has a market capitalization of $16.69 million, a price-to-earnings ratio of -28.00 and a beta of -1.04.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.